Recent Updates
Recently added Catalysts
AURA Positive Sentiment Score: 70/100

Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference

Key Takeaway: Aura Biosciences, a clinical-stage biotechnology company, announced its participation in the 8th Annual Evercore Healthcare Conference. CEO Elisabet de los Pinos is scheduled to partake in a fireside chat on December 2, 2025. The discussion will be accessible via a live webcast and will be archived for 90 days. The company continues to focus on developing precision therapies for solid tumors, particularly in late-stage development for early choroidal melanoma.

Market Sentiment Analysis

POSITIVE FACTORS

  • Aura Biosciences is engaging with the investment community through the conference.
  • The company is focused on developing innovative therapies that aim to preserve organ function.
  • There is a strong focus on advancing their lead candidate, bel-sar (AU-011), in multiple indications.

Full Press Release Details

BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:50 a.m. ET.
The live webcast of the fireside chat will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for early choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.
Investor and Media Relations Contact:
Head of Investor Relations and Corporate Communications

Frequently Asked Questions

Who is participating in the fireside chat?

Elisabet de los Pinos, PhD, CEO of Aura Biosciences will participate.

When is the fireside chat at the Evercore Conference?

The fireside chat is on December 2, 2025, at 10:50 a.m. ET.

Where can I watch the fireside chat webcast?

The webcast will be on the 'Investors & Media' page of Aura's website.

What is Aura Biosciences focused on developing?

Aura Biosciences develops precision therapies for solid tumors.

What is Aura's lead candidate for treatment?

Aura's lead candidate is bel-sar (AU-011) for choroidal melanoma.

Last updated: Nov 24, 2025